The mRNA vaccines were released globally in early 2021 with the slogan “safe and effective.” Unusually for a new class of medicine, they were soon recommended by public health authorities for pregnant women.
By late 2021, working-age women, including those who were pregnant, were being thrown out of employment for not agreeing to be injected.
Those who took the mRNA vaccines did so based on trust in health authorities — the assumption being that they would not have been approved if the evidence was not absolutely clear.
The role of regulatory agencies was to protect the public and, therefore, if they were approved, the “vaccines” were safe.
Recently, a lengthy vaccine evaluation report sponsored by Pfizer and submitted to the Australian regulator, the Therapeutic Goods Administration (TGA) dated January 2021 was released under a Freedom of Information (FOI) request.
The report contains significant new information that had been suppressed by the TGA and by Pfizer itself. Much of this relates directly to the issue of safety in pregnancy and its impacts on the fertility of women of childbearing age.
The whole report is important, but four key data points stand out:
- The rapid decline in antibody and T cells in monkeys following the second dose.
- Biodistribution studies (previously released in 2021 through a FOI request in Japan).
- Data on the impact of fertility outcomes for rats.
- Data on fetal abnormalities in rats.
We focus on the last three items as, for the first point, it is enough to quote the report itself “Antibodies and T cells in monkeys declined quickly over 5 weeks after the second dose of BNT162b2 (V9), raising concerns over long term immunity.”
This point indicates that the regulators should have anticipated the rapid decline in efficacy and must have known at the outset that the initial two-dose “course” was unlikely to confer lasting immunity and would, therefore, require multiple repeat doses.
This expectation of failure was recently highlighted by Dr. Anthony Fauci, former director at the National Institutes of Health (NIH).
The three remaining items should be a major cause for alarm with the pharmaceutical regulatory system.
The first, as revealed in 2021, involved biodistribution studies of the lipid nanoparticle (LNP) carrier in rats, using a luciferase enzyme to substitute for the mRNA vaccine.
The study demonstrated that the vaccine will travel throughout the body after injection, and is found not only at the injection site but in all organs tested, with high concentration in the ovaries, liver, adrenal glands and spleen.
Authorities who assured vaccinated people in early 2021 that the vaccine stays in the arm were, as we have known for two years, lying.
In terms of the impact on fertility and fetal abnormalities, the report includes a study of 44 rats and describes two main metrics, the pre-implantation loss rate and the number of abnormalities per fetus (also expressed per litter). In both cases, the metrics were significantly higher for vaccinated rats than for unvaccinated rats.
Roughly speaking, the pre-implantation loss ratio compares the estimated number of fertilized ova and the ova implanted in the uterus. The table below is taken from the report itself and clearly shows the loss rate for vaccinated (BNT162b2) is more than double the unvaccinated control group.
In a case-control study, a doubling of pregnancy loss in the intervention group would represent a serious safety signal.
Rather than take this seriously, the authors of the report then compared the outcomes to historical data on other rat populations; 27 studies of 568 rats, and ignored the outcome because other populations had recorded higher overall losses; this range is shown in the right-hand column as 2.6% to 13.8%.
This analysis is alarming as remaining below the highest previously recorded pregnancy loss levels in populations elsewhere is not a safe outcome when the intervention is also associated with double the harm of the control group.
A similar pattern is observed for fetal malformations with higher abnormality rate in each of the 12 categories studied. Of the 11 categories where Pfizer confirmed the data is correct, there are only two total abnormalities in the control group, versus 28 with the mRNA vaccine (BNT162b2).
In the category which Pfizer labeled as unreliable (supernumerary lumbar ribs), there were three abnormalities in the control group and 12 in the vaccinated group.
As with the increased pregnancy losses, Pfizer simply ignored the trend and compared the results with historical data from other rat populations. This is very significant as it is seen across every malformation category.
The case-control nature of the study design is again ignored, in order to apparently hide the negative outcomes demonstrated.
These data indicate that there is NO basis for saying the vaccine is safe in pregnancy.
The concentration of LNPs in ovaries, a doubled pregnancy loss rate and raised fetal abnormality rate across all measured categories indicate that designating a safe-in-pregnancy label (B1 category in Australia) was contrary to available evidence.
The data implies that not only was the Government’s “safe and effective” sloganeering not accurate, it was totally misleading with respect to the safety data available….